Top 10 successful drugs in 2021

(RTTNews) – Better safe than sorry. The year 2021 saw the acceleration of the global deployment of vaccines for the prevention of a new disease. Yes, a disease that has been in the headlines since 2020 – Covid-19.

It’s no surprise that Covid-19 vaccines find a place in the list of top-selling pharmaceuticals. In this article, we will introduce you to the top 10 drugs based on data from the first nine months of this year.

# 1. Commirnaty

BioNTech SE (BNTX) / Pfizer Inc. (PFE) Comirnaty, a vaccine to prevent COVID-19, available since last December, has established itself as the bestseller.

The vaccine generated global sales of $ 24.3 billion for the first nine months of 2021 and is expected to generate sales of around $ 36 billion for the year 2021.

Comirnaty, a messenger RNA (mRNA) vaccine is approved as a 2-dose series for the prevention of COVID-19 in people 16 years of age and older. Under the emergency use authorization, the vaccine is authorized as a 2-dose primary series in subjects aged 12 to 15 years, as a third dose of the primary series in immunocompromised individuals aged 12 years and over, and as a single booster dose for subjects aged 16 and 17 years at least six months after the end of the primary vaccination course.

# 2. Humira

Humira from AbbVie Inc. (ABBV), which is used to treat many inflammatory conditions in adults, had global sales of $ 15.36 billion in the first nine months of 2021. The drug generated sales of $ 15.36 billion in the first nine months of 2021. sales of $ 19.8 billion worldwide for the year 2020.

As the first fully human monoclonal antibody to receive FDA approval in December 2002, Humira is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis, juvenile idiopathic arthritis , ulcerative colitis, hidradenitis suppurativa and uveitis.

Humira first appeared on the list of the world’s best-selling drugs in 2012 and held the top spot until 2020.

A total of 6 Humira biosimilars have already been approved in the United States. They have not yet been launched and will enter the market from the end of January 2023.

Meanwhile, another Iceland-based company by the name of Alvotech has also sought FDA approval for its biosimilar version of Humira. AbbVie claimed that Alvotech stole trade secrets related to Humira. However, that case was dismissed by an Illinois federal judge in October of this year. Now AbbVie has asked the United States International Trade Commission to investigate the alleged theft of trade secrets.

# 3. Keytruda

Keytruda of Merck & Co. Inc (MRK), with global sales of $ 12.6 billion for the first nine months of 2021, comes third on the list. Global sales of the drug for the year 2020 amounted to $ 14.4 billion.

Keytruda, which is the first programmed death receptor-1 (PD-1) blocking antibody to be approved, is indicated for a variety of cancers. This cancer drug received its first FDA approval in 2014 for advanced melanoma and has since expanded its label to include more than 15 indications.

Keytruda’s patent would expire in 2028.

# 4. Spikevax

Moderna Inc.’s Spikevax (MRNA), a vaccine to prevent COVID-19, generated sales of $ 10.7 billion for the nine months ended September 30, 2021. Sales of the vaccine are expected to be around of $ 15 billion and $ 18 billion for the year 2021.

Spikevax is also an mRNA vaccine just like BioNTech / Pfizer’s Comirnaty. But Spikevax has yet to gain full FDA approval. It is currently authorized for emergency use as a two-dose primary series for persons 18 years of age and over, as a third dose of the primary series for immunocompromised persons aged 18 and over and as a single booster dose for persons aged 18 and over. 18 years old. years and older at least six months after completing a primary series of the vaccine.

The FDA is reviewing the biologics license application for Spikevax and a decision is expected in April 2022.

# 5. Revlimid

Bristol-Myers Squibb Co.’s (BMY) Revlimid achieved global sales of $ 9.49 billion for the first nine months of 2021. The drug, which generated $ 12.1 billion in annual sales in 2020, was ranked fourth best-selling drugs in the world in 2020.

Revlimid has been on the market since 2006 and is indicated for myelodysplastic syndrome, multiple myeloma, lymphoma, follicular lymphoma.

The first licensed entry of any generic Revlimid in the United States is March 2022, according to the company.

# 6. Eliquis

Eliquis, developed by Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE), fell 3 places to 6th position with $ 8.09 billion in sales for the first nine months of 2021. The drug had stalled third place in 2020, generating annual global sales of $ 14.1 billion.

Approved to reduce the risk of stroke and blood clots in people with an irregular heartbeat known as atrial fibrillation, Eliquis enjoys patent protection until at least 2028, although the generic versions of the drug have already obtained interim approvals from the FDA.

#seven. Imbruvica

Imbruvica, jointly developed and marketed by Johnson & Johnson’s Janssen Biotech Inc. and Pharmacyclics LLC, an AbbVie company, generated worldwide sales of $ 7.33 billion for the first nine months of 2021.

The drug is used to treat mantle cell lymphoma, marginal zone lymphoma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

Since its launch in 2013, sales of Imbruvica have increased significantly. In 2020, Imbruvica’s annual sales were $ 9.44 billion and it was ranked sixth on the bestseller list.

# 8. Eylea

Eylea, developed by Regeneron Pharmaceuticals Inc (REGN) and German pharmaceutical giant Bayer, reported total sales of $ 6.90 billion for the nine months ended September 30, 2021. The drug recorded annual sales of 7.91 billion dollars in 2020, occupying 5th place.

Indicated for the treatment of macular degeneration, macular edema and diabetic retinopathy, Eylea is on the verge of losing patent protection in 2023 in the United States.

# 9. Stelara

Stelara, developed by Johnson & Johnson’s (JNJ) Janssen Biotech Inc, generated global sales of $ 6.80 billion for the first nine months of 2021. The drug, which is approved for the treatment of plaque psoriasis, from l Active psoriatic arthritis, active Crohn’s disease, and active ulcerative colitis, hit the market in 2009 and reached blockbuster status in 2012, recording sales of $ 1.02 billion that year.

With expanded indications, Stelara’s sales gained momentum, and by 2020 the drug had seen annual sales of $ 7.70 billion.

The US patent on Stelara is set to expire in September 2023, and development of biosimilar versions of the drug has already been undertaken by some companies.

#ten. Biktarvy

Biktarvy of Gilead Sciences Inc. (GILD) achieved total revenue of $ 6.09 billion for the first nine months of 2021.

Biktarvy, which is indicated for the treatment of HIV, hit the market in February 2018 and generated annual sales of $ 1.18 billion that year. With the increase in the demand for treatment and the net price, sales of this anti-HIV drug have increased dramatically over the years.

With annual sales of $ 7.26 billion, Biktarvy was in ninth place in 2020.

A generic version of Biktarvy, named Taffic, was launched in December 2019 in India and is marketed and distributed there by Hetero Healthcare. No generic equivalent of the drug has been approved in the United States

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

About Harry Qualls

Harry Qualls

Check Also

Why we use the language of war to talk about the Covid

Much of the pandemic has been described in terms of a “war” on the virus. …